Holen Sie sich die Stockscreener-App
75.54
0.44%
0.33
Handel nachbörslich:
75.54
Schlusskurs vom Vortag:
$75.21
Offen:
$74.16
24-Stunden-Volumen:
1.23M
Relative Volume:
2.14
Marktkapitalisierung:
$4.08B
Einnahmen:
$155.82M
Nettoeinkommen (Verlust:
$-40.42M
KGV:
-19.08
EPS:
-3.96
Netto-Cashflow:
$3.58M
1W Leistung:
-9.86%
1M Leistung:
-13.39%
6M Leistung:
+38.38%
1J Leistung:
+49.11%
1-Tages-Spanne:
$73.40
$76.41
1-Wochen-Bereich:
$73.39
$85.31
52-Wochen-Spanne:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Vergleichen Sie ACLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
75.54 | 4.08B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Geode Capital Management LLC Has $81.43 Million Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX) - Simply Wall St
Arcellx (NASDAQ:ACLX) Shares Down 4.6%Here's Why - MarketBeat
Y Intercept Hong Kong Ltd Sells 11,955 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx's SWOT analysis: biotech stock's potential in CAR-T therapy market - Investing.com Australia
Heba Nowyhed - The Business Journals
Lord Abbett & CO. LLC Boosts Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by State Street Corp - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Up 17.5% in November - MarketBeat
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma - Yahoo Finance
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Arcellx's SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com Canada
Arcellx's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com India
Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - MedCity News
Stifel maintains Buy on Arcellx stock post ASH24 data By Investing.com - Investing.com Canada
Stifel maintains Buy on Arcellx stock post ASH24 data - Investing.com
Arcellx (NASDAQ:ACLX) Earns Buy Rating from HC Wainwright - MarketBeat
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti - BioSpace
ASH: Gilead/Arcellx Point To Anito-Cel’s Safety, High-Risk Patient Advantages - Citeline News & Insights
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. - MSN
Arcellx shares remain a Buy at TD Cowen following anito-cell data release - Investing.com
In-Depth Examination Of 14 Analyst Recommendations For Arcellx - Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - AOL
14 Analysts Have This To Say About Arcellx - Inkl
Arcellx shares target lifted, buy rating continued on positive developments By Investing.com - Investing.com Nigeria
Arcellx shares target lifted, buy rating continued on positive developments - Investing.com
Arcellx (NASDAQ:ACLX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Arcellx, Inc. Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed or Refractory Multiple Myeloma to Be Presented During an Oral Presentation At the 66Th Ash Annual Meeting and Exposition - Marketscreener.com
Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole - TipRanks
Arcellx's Multiple Myeloma Treatment Shows Breakthrough 97% Response Rate in Phase 2 Trial - StockTitan
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire
Leerink Partnrs Reduces Earnings Estimates for Arcellx - MarketBeat
Jacobs Levy Equity Management Inc. Has $6.68 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx director Kavita Patel sells $137,817 in stock By Investing.com - Investing.com Canada
Arcellx director Kavita Patel sells $137,817 in stock - Investing.com
Arcellx, Inc. (NASDAQ:ACLX) is Samsara BioCapital LLC's 6th Largest Position - MarketBeat
RA Capital Management L.P. Acquires 247,465 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Citigroup Inc. Purchases 21,262 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
The Manufacturers Life Insurance Company Increases Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Parkman Healthcare Partners LLC Sells 90,351 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Janus Henderson Group PLC Has $168.03 Million Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Erste Asset Management GmbH Takes Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
(ACLX) Trading Signals - Stock Traders Daily
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx price target raised to $115 from $73 at Barclays - MSN
Intech Investment Management LLC Acquires Shares of 9,579 Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Suvretta Capital Management LLC Sells 826,304 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Fmr LLC Has $541.08 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Acuta Capital Partners LLC Has $5.19 Million Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
FORA Capital LLC Purchases Shares of 12,935 Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcellx Inc-Aktie (ACLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Kavita | Director |
Dec 03 '24 |
Sale |
91.88 |
1,500 |
137,818 |
0 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Nov 19 '24 |
Option Exercise |
8.66 |
3,000 |
25,980 |
3,000 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Nov 15 '24 |
Sale |
88.87 |
1,761 |
156,508 |
0 |
| Patel Kavita | Director |
Nov 12 '24 |
Option Exercise |
6.66 |
1,500 |
9,990 |
1,500 |
| Patel Kavita | Director |
Nov 12 '24 |
Sale |
106.33 |
1,500 |
159,495 |
0 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Nov 08 '24 |
Option Exercise |
8.66 |
7,200 |
62,352 |
14,115 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Nov 08 '24 |
Sale |
100.55 |
12,354 |
1,242,170 |
1,761 |
| Patel Kavita | Director |
Nov 08 '24 |
Option Exercise |
13.03 |
33,763 |
439,925 |
33,763 |
| Patel Kavita | Director |
Nov 11 '24 |
Option Exercise |
15.00 |
15,238 |
228,570 |
15,238 |
| Patel Kavita | Director |
Nov 07 '24 |
Option Exercise |
6.66 |
8,478 |
56,463 |
8,478 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):